A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease
Status:
Completed
Trial end date:
2018-06-08
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the effect of CK-2127107 relative to placebo on cycle
ergometer exercise tolerance, assessed as change from period baseline in constant work rate
(CWR) endurance time, utilizing a breath-by-breath metabolic measurement system with
integrated electrocardiogram (ECG). The time to intolerance was assessed by a stopwatch and
verified from electronic recordings of the cycle ergometer.
This study assessed cardiopulmonary and neuromuscular effects of CK-2127107 relative to
placebo; the effect of CK-2127107 on resting spirometry relative to placebo; the safety and
tolerability of CK-2127107 as well as the pharmacokinetics of CK-2127107.